Haleon PLC has been making deliberate strides in the stock market. Their stocks took a brief hit, plunging 2.08% in two days and hitting an April 2025 low, but strategists like Kepler Capital maintained a 'Buy' position on the stock. Haleon seeked to bolster its share price with an aggressive share buyback program, purchasing significant amounts of its own shares. Pharmaceutical giant Pfizer sold its entire Haleon stake for $3.24 billion, causing some stock market stir.
Despite this, Haleon continues to make strategic moves with an announced partnership with Brightseed, restructuring of financial reporting categories for clarity, and a major reshuffle of their executive department. The consumer healthcare brand also anticipates 2025 revenue growth, with analysts affirming that the company still makes for a good long-term investment.
Notably, the company completed the first tranche of its share buyback program while disclosing more PDMR share transactions. The buyback program, a part of Haleon's capital management strategy, was executed while the company maintained confidence in its 2025 targets. Lastly, Haleon took full control of a Chinese consumer healthcare venture.
Haleon Stocks News Analytics from Tue, 01 Oct 2024 07:00:00 GMT to Sat, 19 Jul 2025 15:42:21 GMT - Rating 3 - Innovation 6 - Information 8 - Rumor -4
